84.38
0.54%
-0.46
Handel nachbörslich:
84.00
-0.38
-0.45%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$84.84
Offen:
$86.32
24-Stunden-Volumen:
5.06M
Relative Volume:
1.32
Marktkapitalisierung:
$33.81B
Einnahmen:
$3.95B
Nettoeinkommen (Verlust:
$680.80M
KGV:
50.53
EPS:
1.67
Netto-Cashflow:
$535.00M
1W Leistung:
+8.51%
1M Leistung:
+8.46%
6M Leistung:
-26.38%
1J Leistung:
-32.74%
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Vergleichen Sie DXCM mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
84.38 | 33.81B | 3.95B | 680.80M | 535.00M | 1.67 |
ABT
Abbott Laboratories
|
113.48 | 196.83B | 41.22B | 5.77B | 6.49B | 3.29 |
SYK
Stryker Corp
|
383.42 | 146.17B | 21.97B | 3.59B | 3.21B | 9.33 |
BSX
Boston Scientific Corp
|
98.66 | 145.41B | 15.91B | 1.79B | 1.89B | 1.21 |
MDT
Medtronic Plc
|
88.08 | 112.94B | 33.00B | 4.29B | 5.50B | 3.27 |
EW
Edwards Lifesciences Corp
|
69.78 | 41.16B | 6.60B | 4.16B | 490.10M | 6.93 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
2023-03-29 | Eingeleitet | UBS | Buy |
2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
2022-10-18 | Eingeleitet | Barclays | Equal Weight |
2022-10-12 | Eingeleitet | Jefferies | Buy |
2022-07-15 | Eingeleitet | Bernstein | Outperform |
2022-03-02 | Fortgesetzt | BofA Securities | Buy |
2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
2021-07-21 | Fortgesetzt | Cowen | Outperform |
2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
2021-05-25 | Eingeleitet | Barclays | Overweight |
2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
2021-01-06 | Hochstufung | UBS | Neutral → Buy |
2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
2020-05-27 | Bestätigt | Piper Sandler | Overweight |
2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
2020-03-05 | Eingeleitet | Citigroup | Buy |
2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
2019-10-23 | Eingeleitet | Stifel | Buy |
2018-11-28 | Eingeleitet | UBS | Neutral |
2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
2018-04-04 | Eingeleitet | Goldman | Sell |
2018-04-04 | Eingeleitet | Guggenheim | Neutral |
2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
Top 10 Medical Device Predictions for 2025 - GlobeNewswire Inc.
Wealthcare Advisory Partners LLC Has $998,000 Position in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Gateway Investment Advisers LLC - MarketBeat
DexCom, Inc. (NASDAQ:DXCM) Sees Significant Decline in Short Interest - MarketBeat
DexCom raised to outperform by Baird - MSN
Dexcom inks glucose biosensor partnership with Life Time - Drug Delivery Business News
DexCom (NASDAQ:DXCM) shareholder returns have been decent, earning 44% in 5 years - Yahoo Finance
DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Sax Wealth Advisors LLC - MarketBeat
Avanza Fonder AB Takes Position in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
Legacy Wealth Asset Management LLC Acquires New Position in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback - Seeking Alpha
Woodstock Corp Cuts Holdings in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
DexCom (NASDAQ:DXCM) Stock Price Up 3.7%Here's What Happened - MarketBeat
JPM25 recap: Robotics, PFA and OTC glucose sensors in the spotlight - MedTech Dive
Baird R W Upgrades DexCom (NASDAQ:DXCM) to Strong-Buy - MarketBeat
Latin America Continuous Glucose Monitoring Device Market Projected To Witness Substantial Growth, - EIN News
Fifth Third Wealth Advisors LLC Has $477,000 Position in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Oak Thistle LLC - MarketBeat
DexCom (NASDAQ:DXCM) Stock Unloaded Rep. Kevin Hern - MarketBeat
DexCom Stock Up Following Strong Preliminary Q4 Results & 2025 Outlook - MSN
Why DexCom, Inc. (DXCM) Is Skyrocketing - Insider Monkey
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DexCom raised to outperform by Baird (DXCM:NASDAQ) - Seeking Alpha
Piper Sandler bullish on DexCom shares citing growth potential and new catalysts - MSN
Baird raises DexCom stock to outperform, target to $104 - MSN
Expert Outlook: DexCom Through The Eyes Of 11 Analysts - Benzinga
This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Outlook Wealth Advisors LLC Buys New Stake in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
DexCom (NASDAQ:DXCM) Upgraded by Robert W. Baird to Outperform Rating - MarketBeat
2 Healthcare Stocks to Buy Hand Over Fist in January - Yahoo Finance
DexCom, Inc. (NASDAQ:DXCM) Holdings Decreased by Assenagon Asset Management S.A. - MarketBeat
180 Wealth Advisors LLC Invests $255,000 in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
Dexcom CEO talks Stelo sensor launch, OTC strategy - MedTech Dive
Earnings Summary: DexCom reports preliminary Q4 2024 results - AlphaStreet
JP Morgan 2025: Dexcom shares up 5% after 2025 outlook forecasts $4.6bn in revenue - Yahoo Finance
DexCom revenue increases 8% in Q4 2024 - Medical Buyer
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - MSN
DexCom (NASDAQ:DXCM) Shares Gap UpShould You Buy? - MarketBeat
CHICAGO TRUST Co NA Grows Stock Holdings in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
DexCom stock rises on 2025 outlook - MSN
DexCom stock gains, sees 14% revenue growth in 2025 By Investing.com - Investing.com Canada
DexCom stock gains, sees 14% revenue growth in 2025 - Investing.com India
DexCom stock rises on 2025 outlook (NASDAQ:DXCM) - Seeking Alpha
DexCom Q4 Revenue Hits $1.1B as International Sales Surge 17%, Sets Ambitious 2025 Growth Target - StockTitan
DexCom price target raised to $89 from $86 at Bernstein - MSN
Abbott, Dexcom End UPC Feud Over Glucose Monitor Patent - Law360
DexCom (NASDAQ:DXCM) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
42,021 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by Watts Gwilliam & Co. LLC - MarketBeat
DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by First Hawaiian Bank - MarketBeat
Diversified Trust Co Lowers Position in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
Why Is Jim Cramer Mystified by DexCom, Inc. (DXCM)’s Earnings Miss and Competitive Challenges? - Insider Monkey
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):